CIK 0001640266 · Accelerated filer<br>Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-06 | GERAGHTY JAMES A Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2023-06-06 | SCANGOS GEORGE A Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2023-06-06 | Hyman Steven Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2023-05-09 | SCANGOS GEORGE A Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2023-04-03 | Sandrock Alfred President and CEO | Sale | −7,437 | $7.83 | $58K | 214,618 |
| 2023-04-03 | Swartz Robin Chief Operating Officer | Sale | −1,259 | $7.83 | $10K | 71,617 |
| 2023-02-23 | NEUROCRINE BIOSCIENCES INC 10% owner | Purchase | +4,395,588 | $8.88 | $39.0M | 8,575,316 |
| 2015-11-16 | Sanofi Former 10% owner | Purchase | +125,000 | $14.00 | $1.8M | 2,477,941 |
| 2015-11-10 | Sanofi Former 10% owner | Conversion | +2,352,941 | 2,352,941 | ||
| 2015-11-10 | Sanofi Former 10% owner | Conversion · Shares of Series B convertible preferred stock | −10,000,000 | 0 |
Page 7 of 7 · 130 trades